Adicet Bio
ACET
56 hedge funds and large institutions have $42M invested in Adicet Bio in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 12 closing their positions.
143% more call options, than puts
Call options by funds: $34K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.15% less ownership
Funds ownership: 4.37% → 4.22% (-0.15%)
13% less funds holding
Funds holding: 64 → 56 (-8)
24% less capital invested
Capital invested by funds: $55.4M → $42M (-$13.4M)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.1M |
| 2 |
WIA
Wealthedge Investment Advisors
New York
|
+$138K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$69.4K |
| 4 |
Goldman Sachs
New York
|
+$56.9K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$32.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$528K |
| 2 |
Norges Bank
Oslo,
Norway
|
-$413K |
| 3 |
D.E. Shaw & Co
New York
|
-$305K |
| 4 |
Two Sigma Investments
New York
|
-$186K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$171K |
ACET Hedge Fund Activity: Q1 2025 in Review
56 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2025, worth a combined $42M — down 24% from $55.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ACET and 4 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, adding an estimated $1.1M. The largest seller was Millennium Management, cutting an estimated $528K.
- 56 institutional investors held Adicet Bio (ACET) as of Q1 2025, down from 64 in Q4 2024.
- Funds reported $42M of Adicet Bio stock for Q1 2025, down 24% quarter-over-quarter.
- 4 funds opened new Adicet Bio positions in Q1 2025 and 12 closed out, a net change of -8 holders.
- The largest Adicet Bio buyer in Q1 2025 was Citadel Advisors, an estimated $1.1M added.
- The largest Adicet Bio seller in Q1 2025 was Millennium Management, an estimated $528K sold.
Based on aggregated 13F filings for Q1 2025.